All
Maral Kibarian Skelsey, MD, Shares Insights Into DermTech’s 2-GEP Assay Success
January 22nd 2024DermTech’s study results demonstrated that in patients with Fitzpatrick skin types IV-VI, all 3 melanomas diagnosed by histopathology were correctly identified by the 2-GEP assay as positive for LINC00518 and PRAME.
Previewing Editorial Advisory Board Member Sessions at the Maui Derm Hawaii 2024 Conference
January 19th 2024Among the many sessions to be held at the Maui Derm Hawaii 2024 conference on Maui, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.
Rare Immune Cell May Predict Immunotherapy Response in Melanoma
January 18th 2024Vd1-gd T cells, a rare type of immune cell, have been found to potentially predict how likely it is that certain patients with advanced skin cancer will be responsive to treatment via immunotherapy, according to recently published research.